{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:45:10Z","timestamp":1787589910670,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"},{"name":"Shanghai LianBio Development Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40119-025-00409-5","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T01:22:09Z","timestamp":1745889729000},"page":"267-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study"],"prefix":"10.1007","volume":"14","author":[{"given":"Zhuang","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian\u2019an","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Mao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Chen","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-0029","authenticated-orcid":false,"given":"Shuyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"37","key":"409_CR1","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503\u2013626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194.","journal-title":"Eur Heart J"},{"issue":"7","key":"409_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379(7):655\u201368. https:\/\/doi.org\/10.1056\/NEJMra1710575.","journal-title":"N Engl J Med"},{"issue":"7","key":"409_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749\u201370. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311059.","journal-title":"Circ Res"},{"issue":"1","key":"409_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12551-017-0274-6","volume":"10","author":"DV Trivedi","year":"2018","unstructured":"Trivedi DV, Adhikari AS, Sarkar SS, et al. Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light. Biophys Rev. 2018;10(1):27\u201348. https:\/\/doi.org\/10.1007\/s12551-017-0274-6.","journal-title":"Biophys Rev"},{"key":"409_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10050951","author":"A Argiro","year":"2021","unstructured":"Argiro A, Zampieri M, Berteotti M, et al. Emerging medical treatment for hypertrophic cardiomyopathy. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10050951.","journal-title":"J Clin Med"},{"key":"409_CR6","doi-asserted-by":"publisher","unstructured":"Authors\/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733\u201379. https:\/\/doi.org\/10.1093\/eurheartj\/ehu284.","DOI":"10.1093\/eurheartj\/ehu284"},{"issue":"4","key":"409_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJMoa021332","volume":"348","author":"MS Maron","year":"2003","unstructured":"Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295\u2013303. https:\/\/doi.org\/10.1056\/NEJMoa021332.","journal-title":"N Engl J Med"},{"issue":"7","key":"409_CR8","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2004.12.067","volume":"45","author":"C Autore","year":"2005","unstructured":"Autore C, Bernabo P, Barilla CS, et al. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol. 2005;45(7):1076\u201380. https:\/\/doi.org\/10.1016\/j.jacc.2004.12.067.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"409_CR9","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1111\/echo.14539","volume":"36","author":"HM Badran","year":"2019","unstructured":"Badran HM, Soltan G, Almeleigi R, et al. Prognostic significance of left ventricular end diastolic pressure using E\/E\u2019 in patients with hypertrophic cardiomyopathy. Echocardiography. 2019;36(12):2167\u201375. https:\/\/doi.org\/10.1111\/echo.14539.","journal-title":"Echocardiography"},{"issue":"25","key":"409_CR10","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):e159\u2013240. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.045.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"409_CR11","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","volume":"49","author":"MP Grillo","year":"2019","unstructured":"Grillo MP, Erve JCL, Dick R, et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica. 2019;49(6):718\u201333. https:\/\/doi.org\/10.1080\/00498254.2018.1495856.","journal-title":"Xenobiotica"},{"issue":"40","key":"409_CR12","doi-asserted-by":"publisher","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","volume":"292","author":"RF Kawas","year":"2017","unstructured":"Kawas RF, Anderson RL, Ingle SRB, et al. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017;292(40):16571\u20137. https:\/\/doi.org\/10.1074\/jbc.M117.776815.","journal-title":"J Biol Chem"},{"issue":"35","key":"409_CR13","doi-asserted-by":"publisher","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","volume":"115","author":"RL Anderson","year":"2018","unstructured":"Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci USA. 2018;115(35):E8143\u201352. https:\/\/doi.org\/10.1073\/pnas.1809540115.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10253","key":"409_CR14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X.","journal-title":"Lancet"},{"issue":"6","key":"409_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","volume":"143","author":"S Saberi","year":"2021","unstructured":"Saberi S, Cardim N, Yamani M, et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation. 2021;143(6):606\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052359.","journal-title":"Circulation"},{"issue":"25","key":"409_CR16","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","volume":"78","author":"SM Hegde","year":"2021","unstructured":"Hegde SM, Lester SJ, Solomon SD, et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78(25):2518\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2021.09.1381.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"409_CR17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","volume":"8","author":"Z Tian","year":"2023","unstructured":"Tian Z, Li L, Li X, et al. Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial. JAMA Cardiol. 2023;8(10):957\u201365. https:\/\/doi.org\/10.1001\/jamacardio.2023.3030.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"409_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39 e14. https:\/\/doi.org\/10.1016\/j.echo.2014.10.003.","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"409_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","volume":"32","author":"C Mitchell","year":"2019","unstructured":"Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1\u201364. https:\/\/doi.org\/10.1016\/j.echo.2018.06.004.","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"409_CR20","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/s0735-1097(00)00531-3","volume":"35","author":"CP Green","year":"2000","unstructured":"Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245\u201355. https:\/\/doi.org\/10.1016\/s0735-1097(00)00531-3.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"409_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","volume":"10","author":"M Nassif","year":"2022","unstructured":"Nassif M, Fine JT, Dolan C, et al. Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2022;10(8):531\u20139. https:\/\/doi.org\/10.1016\/j.jchf.2022.03.002.","journal-title":"JACC Heart Fail"},{"issue":"10","key":"409_CR22","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","volume":"8","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Wolski K, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol. 2023;8(10):968\u201377. https:\/\/doi.org\/10.1001\/jamacardio.2023.3342.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"409_CR23","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.21037\/jtd-22-182","volume":"14","author":"SA Guigui","year":"2022","unstructured":"Guigui SA, Torres C, Escolar E, et al. Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review. J Thorac Dis. 2022;14(6):2309\u201325. https:\/\/doi.org\/10.21037\/jtd-22-182.","journal-title":"J Thorac Dis"},{"issue":"1","key":"409_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ejhf.971","volume":"20","author":"SF Nagueh","year":"2018","unstructured":"Nagueh SF. Non-invasive assessment of left ventricular filling pressure. Eur J Heart Fail. 2018;20(1):38\u201348. https:\/\/doi.org\/10.1002\/ejhf.971.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"409_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","volume":"29","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277\u2013314. https:\/\/doi.org\/10.1016\/j.echo.2016.01.011.","journal-title":"J Am Soc Echocardiogr"},{"key":"409_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.015","author":"A Masri","year":"2024","unstructured":"Masri A, Cardoso RN, Abraham TP, et al. Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy. J Am Coll Cardiol. 2024. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.015.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"409_CR27","doi-asserted-by":"publisher","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","volume":"320","author":"PO Awinda","year":"2021","unstructured":"Awinda PO, Watanabe M, Bishaw Y, et al. Mavacamten decreases maximal force and Ca(2+) sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2021;320(2):H881\u201390. https:\/\/doi.org\/10.1152\/ajpheart.00345.2020.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6273","key":"409_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351(6273):617\u201321. https:\/\/doi.org\/10.1126\/science.aad3456.","journal-title":"Science"},{"issue":"30","key":"409_CR29","doi-asserted-by":"publisher","first-page":"eabo7622","DOI":"10.1126\/sciadv.abo7622","volume":"9","author":"S Nag","year":"2023","unstructured":"Nag S, Gollapudi SK, Del Rio CL, et al. Mavacamten, a precision medicine for hypertrophic cardiomyopathy: from a motor protein to patients. Sci Adv. 2023;9(30):eabo7622. https:\/\/doi.org\/10.1126\/sciadv.abo7622.","journal-title":"Sci Adv"},{"issue":"7","key":"409_CR30","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/echo.13857","volume":"35","author":"JP Costabel","year":"2018","unstructured":"Costabel JP, Galve E, Terricabras M, et al. E\/e\u2019 ratio and left atrial area are predictors of atrial fibrillation in patients with hypertrophic cardiomyopathy. Echocardiography. 2018;35(7):935\u201340. https:\/\/doi.org\/10.1111\/echo.13857.","journal-title":"Echocardiography"},{"issue":"1","key":"409_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/ehjci\/jex134","volume":"19","author":"DY Lu","year":"2018","unstructured":"Lu DY, Haileselassie B, Ventoulis I, et al. E\/e\u2019 ratio and outcome prediction in hypertrophic cardiomyopathy: the influence of outflow tract obstruction. Eur Heart J Cardiovasc Imaging. 2018;19(1):101\u20137. https:\/\/doi.org\/10.1093\/ehjci\/jex134.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"409_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004052","author":"P Debonnaire","year":"2017","unstructured":"Debonnaire P, Joyce E, Hiemstra Y, et al. Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation. Circ Arrhythm Electrophysiol. 2017. https:\/\/doi.org\/10.1161\/CIRCEP.116.004052.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"9","key":"409_CR33","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2459\/JCM.0b013e3283383355","volume":"11","author":"B Pinamonti","year":"2010","unstructured":"Pinamonti B, Merlo M, Nangah R, et al. The progression of left ventricular systolic and diastolic dysfunctions in hypertrophic cardiomyopathy: clinical and prognostic significance. J Cardiovasc Med (Hagerstown). 2010;11(9):669\u201377. https:\/\/doi.org\/10.2459\/JCM.0b013e3283383355.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"7","key":"409_CR34","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.amjcard.2006.05.013","volume":"98","author":"S Nistri","year":"2006","unstructured":"Nistri S, Olivotto I, Betocchi S, et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol. 2006;98(7):960\u20135. https:\/\/doi.org\/10.1016\/j.amjcard.2006.05.013.","journal-title":"Am J Cardiol"},{"issue":"12","key":"409_CR35","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.echo.2009.09.016","volume":"22","author":"WI Yang","year":"2009","unstructured":"Yang WI, Shim CY, Kim YJ, et al. Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2009;22(12):1338\u201343. https:\/\/doi.org\/10.1016\/j.echo.2009.09.016.","journal-title":"J Am Soc Echocardiogr"},{"issue":"25","key":"409_CR36","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","volume":"78","author":"AM Dybro","year":"2021","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR, et al. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78(25):2505\u201317. https:\/\/doi.org\/10.1016\/j.jacc.2021.07.065.","journal-title":"J Am Coll Cardiol"},{"key":"409_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132913","author":"A Guler","year":"2025","unstructured":"Guler A, Erata YE, Demirtola AI, et al. The effect of disopyramide therapy on functional capacity improvement in patients with obstructive hypertrophic cardiomyopathy. Int J Cardiol. 2025. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132913.","journal-title":"Int J Cardiol"},{"issue":"10293","key":"409_CR38","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","volume":"397","author":"JA Spertus","year":"2021","unstructured":"Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10293):2467\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(21)00763-7.","journal-title":"Lancet"},{"issue":"19","key":"409_CR39","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1161\/CIRCULATIONAHA.123.067470","volume":"150","author":"SV Arnold","year":"2024","unstructured":"Arnold SV, Gosch KL, Dolan C, et al. Association of echocardiographic parameters and health status in patients with obstructive hypertrophic cardiomyopathy: insights from EXPLORER-HCM. Circulation. 2024;150(19):1560\u20132. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067470.","journal-title":"Circulation"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00409-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00409-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00409-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T22:48:40Z","timestamp":1747435720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00409-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00409-5","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors reported medical writing support for the manuscript from Bristol Myers Squibb. Yu-Mao Chen, Yue Zhong, Yu Chen Barrett, and Jing Zheng are employees of Bristol Myers Squibb and own stocks of Bristol Myers Squibb. Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian'an Wang, Yunqi Shi, Daoquan Peng, Ping Yang, Wei Ma, Fang Wang, Wei Jin, Xiang Cheng, and Shuyang Zhang confirm that they have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This trial was conducted in accordance with the principles of the Declaration of Helsinki and Guideline for Good Clinical Practice. The protocol has been approved by institutional review boards\/ethics committees at each site. All patients have provided written informed consent prior to entering study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}